Skip to main content
Clinical Trials/NCT06614504
NCT06614504RecruitingPhase 2

A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users

University of Vermont2 sites in 1 country308 target enrollmentStarted: November 1, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Enrollment
308
Locations
2
Primary Endpoint
Number of cigarettes smoked per day

Study Overview

Brief Summary

Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial
Primary Purpose
Other
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Regular use of tobacco
  • •21 year of age or older
  • •Speak, comprehend and read English well enough to complete study procedures

Exclusion Criteria

  • •Pregnant, trying to become pregnant, or nursing
  • •Under the age of 21
  • •Health conditions that could undermine ability to complete the study

Arms & Interventions

RC 1 + REC 1

Experimental

Research cigarettes #1 plus research e-cigarettes #1

Intervention: Varying the nicotine content of cigarettes (Other)

RC 1 + REC 1

Experimental

Research cigarettes #1 plus research e-cigarettes #1

Intervention: Varying the nicotine content of e-cigarettes (Other)

RC 1 + REC 2

Experimental

Research cigarettes #1 plus research e-cigarettes #2

Intervention: Varying the nicotine content of cigarettes (Other)

RC 1 + REC 2

Experimental

Research cigarettes #1 plus research e-cigarettes #2

Intervention: Varying the nicotine content of e-cigarettes (Other)

RC 2 + REC 1

Experimental

Research cigarettes #2 plus research cigarettes #1

Intervention: Varying the nicotine content of cigarettes (Other)

RC 2 + REC 1

Experimental

Research cigarettes #2 plus research cigarettes #1

Intervention: Varying the nicotine content of e-cigarettes (Other)

RC 2 + REC 2

Experimental

Research cigarettes #2 + research e-cigarettes #2

Intervention: Varying the nicotine content of cigarettes (Other)

RC 2 + REC 2

Experimental

Research cigarettes #2 + research e-cigarettes #2

Intervention: Varying the nicotine content of e-cigarettes (Other)

Outcomes

Primary Outcomes

Number of cigarettes smoked per day

Time Frame: 12 weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Elias Klemperer

Assistant Professor

University of Vermont

Study Sites (2)

Loading locations...

Similar Trials